Literature DB >> 10870734

Neurotrophic factors and pain.

S C Apfel1.   

Abstract

Neurotrophic factors have been shown to play significant roles in the transmission of physiologic and pathologic pain. Nerve growth factor appears to be particularly important. It is crucial for the development of sympathetic and small fiber sensory neurons that serve as nociceptors. It stimulates the expression and release of neuropeptides involved in pain transmission, and interacts with cellular and molecular mediators of inflammation. Blockade with nerve growth factor antiserum demonstrates the critical role of the growth factor in mediating inflammatory hyperalgesia. Administration of nerve growth factor to rodents results in the rapid onset of hyperalgesia. Although the exact mechanism is unknown, several possibilities have been proposed. In clinical trials for the treatment of Alzheimer disease and peripheral neuropathy, induction of pain has been the major adverse event. When administered intracebrebroventricularly, a dull constant back pain resulted. Subcutaneous injection of nerve growth factor induces injection site hyperalgesia, as well as generalized myalgias and arthralgias. Whether the mechanisms underlying these adverse events are identical to those associated with the hyperalgesia in rodents is unknown. In addition to nerve growth factor, other growth factors, such as brain-derived neurotrophic factor and glial cell-derived neurotrophic factor, may be involved in pain pathways. Their precise roles are still being defined, but evidence suggests that they may have particular relevance to neuropathic pain. Understanding the role all these factors play may change the way we approach the treatment of pain in general, and neuropathic pain in particular.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10870734     DOI: 10.1097/00002508-200006001-00003

Source DB:  PubMed          Journal:  Clin J Pain        ISSN: 0749-8047            Impact factor:   3.442


  14 in total

1.  Augmenting glial cell-line derived neurotrophic factor signaling to treat painful neuropathies.

Authors:  Ahmet Höke
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-28       Impact factor: 11.205

2.  Adenomyosis: Mechanisms and Pathogenesis.

Authors:  Junyu Zhai; Silvia Vannuccini; Felice Petraglia; Linda C Giudice
Journal:  Semin Reprod Med       Date:  2020-10-08       Impact factor: 1.303

3.  Swedish Nerve Growth Factor Mutation (NGFR100W) Defines a Role for TrkA and p75NTR in Nociception.

Authors:  Kijung Sung; Luiz F Ferrari; Wanlin Yang; ChiHye Chung; Xiaobei Zhao; Yingli Gu; Suzhen Lin; Kai Zhang; Bianxiao Cui; Matthew L Pearn; Michael T Maloney; William C Mobley; Jon D Levine; Chengbiao Wu
Journal:  J Neurosci       Date:  2018-02-26       Impact factor: 6.167

Review 4.  Emerging therapy for diabetic neuropathy: cell therapy targeting vessels and nerves.

Authors:  Hyongbum Kim; Julie J Kim; Young-sup Yoon
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2012-06       Impact factor: 2.895

5.  Innervation in women with uterine myoma and adenomyosis.

Authors:  Ye Jin Choi; Ji-Ae Chang; Young Ah Kim; Sun Hee Chang; Kyoung Chul Chun; Jae Whoan Koh
Journal:  Obstet Gynecol Sci       Date:  2015-03-16

6.  Targeting Cdk5 activity in neuronal degeneration and regeneration.

Authors:  Jyotshnabala Kanungo; Ya-li Zheng; Niranjana D Amin; Harish C Pant
Journal:  Cell Mol Neurobiol       Date:  2009-12       Impact factor: 5.046

7.  The biochemical origin of pain: the origin of all pain is inflammation and the inflammatory response. Part 2 of 3 - inflammatory profile of pain syndromes.

Authors:  Sota Omoigui
Journal:  Med Hypotheses       Date:  2007-08-28       Impact factor: 1.538

8.  Taking pain out of NGF: a "painless" NGF mutant, linked to hereditary sensory autonomic neuropathy type V, with full neurotrophic activity.

Authors:  Simona Capsoni; Sonia Covaceuszach; Sara Marinelli; Marcello Ceci; Antonietta Bernardo; Luisa Minghetti; Gabriele Ugolini; Flaminia Pavone; Antonino Cattaneo
Journal:  PLoS One       Date:  2011-02-28       Impact factor: 3.240

9.  Cell therapy for diabetic neuropathy using adult stem or progenitor cells.

Authors:  Ji Woong Han; Min Young Sin; Young-Sup Yoon
Journal:  Diabetes Metab J       Date:  2013-04       Impact factor: 5.376

10.  Current advances in using neurotrophic factors to treat neurodegenerative disorders.

Authors:  April M Weissmiller; Chengbiao Wu
Journal:  Transl Neurodegener       Date:  2012-07-26       Impact factor: 8.014

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.